In a patient with a pituitary mass, a prolactin level of 85 ng/mL and a low morning cortisol after a dexamethasone suppression test, what is the appropriate management?

Management of Pituitary Mass with Prolactin 85 ng/mL and Low Morning Cortisol Post-Dexamethasone

This patient most likely has a prolactinoma causing stalk compression and secondary adrenal insufficiency; initiate cabergoline as first-line therapy and start glucocorticoid replacement with hydrocortisone 15-25 mg daily before considering any thyroid hormone replacement. 1

Initial Diagnostic Interpretation

The prolactin level of 85 ng/mL in the context of a pituitary mass strongly suggests a prolactinoma rather than stalk effect alone. While stalk compression typically causes prolactin elevations <100 ng/mL, levels between 50-100 ng/mL can represent either entity. The key distinction: prolactinomas generally cause proportional prolactin elevation to tumor size, whereas non-prolactin-secreting masses with stalk compression rarely exceed 100 ng/mL regardless of size 1.

The low morning cortisol following dexamethasone suppression indicates secondary adrenal insufficiency from pituitary dysfunction—this is critical for immediate management as it affects morbidity and mortality risk.

Immediate Management Algorithm

Step 1: Initiate Glucocorticoid Replacement FIRST

• Start hydrocortisone 15-25 mg daily (divided 2-3 times daily) immediately 2
• Alternative: prednisone 4-6 mg daily if hydrocortisone unavailable
• Critical pitfall: Never start thyroid hormone replacement before glucocorticoids in hypopituitarism—this can precipitate adrenal crisis by increasing cortisol metabolism 3

Step 2: Complete Hormonal Evaluation

Measure the following to assess full pituitary function 4:

• Free T4 and TSH (morning levels)
• ACTH (morning, simultaneous with cortisol)
• IGF-1 (screen for growth hormone excess)
• LH, FSH, testosterone (men) or estradiol (women)
• DHEA-S (supports adrenal insufficiency diagnosis if low)

The morning cortisol <150 nmol/L (5 μg/dL) after dexamethasone confirms very likely persistent adrenal insufficiency requiring continued replacement 5.

Step 3: Obtain Pituitary MRI with Contrast

• Assess tumor size, suprasellar extension, and optic chiasm proximity
• Determine if macroadenoma (≥10 mm) or microadenoma (<10 mm)
• Evaluate for cystic components or hemorrhage

Step 4: Visual Field Testing

Formal visual field assessment is mandatory if:

• Macroadenoma present
• Tumor within 3-5 mm of optic chiasm
• Any visual symptoms reported 6, 4

Primary Treatment Decision

Medical Therapy: First-Line for Prolactinomas

Initiate cabergoline 0.5 mg twice weekly as primary treatment 1:

• Cabergoline is superior to bromocriptine (better efficacy, fewer side effects)
• Expected outcomes: prolactin normalization in 80-90%, tumor shrinkage in 70-90%
• Recheck prolactin and visual fields in 4 weeks
• Titrate dose based on prolactin response (maximum 3 mg weekly)

Continue dopamine agonist therapy even during pregnancy if 1:

• Macroadenoma abutting optic chiasm
• Invasive tumor characteristics
• No prior surgery/radiation

When to Consider Surgery Instead

Transsphenoidal surgery should be first-line if 1, 7:

• Severe visual field defects requiring urgent decompression
• Predominantly cystic prolactinoma (dopamine agonists less effective) 8
• Intolerance to dopamine agonists with significant side effects
• Patient preference after informed discussion (microadenomas have 94% cure rate) 7

Common pitfall: The presence of visual field defects alone doesn't mandate surgery—many improve rapidly with cabergoline within weeks. However, progressive visual loss or severe defects warrant urgent surgical consultation 9.

Monitoring Protocol

Short-term (First 3 months):

• Prolactin level at 4 weeks
• Visual fields at 4 weeks if initially abnormal
• MRI at 3 months to assess tumor response
• Monitor for dopamine agonist side effects (nausea, orthostatic hypotension, impulse control disorders)

Long-term:

• Prolactin every 3-6 months until normalized, then annually
• MRI annually until stable shrinkage, then every 2-3 years 4
• Annual pituitary hormone evaluation for 1-2 years to detect new deficiencies 4
• Consider tapering cabergoline after 2+ years if prolactin normalized and no visible tumor on MRI 1

Special Considerations for Adrenal Insufficiency

Stress dose coverage is essential 5:

• Minor illness: double or triple usual dose
• Major stress/surgery: hydrocortisone 100 mg IV every 8 hours
• Patient education on sick day rules and emergency injection kit

Recovery assessment 5:

• Repeat morning cortisol after several months on physiologic replacement
• If cortisol >300 nmol/L (10 μg/dL): consider stopping glucocorticoids
• If 150-300 nmol/L (5-10 μg/dL): continue replacement, recheck in weeks-months
• If <150 nmol/L (5 μg/dL): continue replacement, recheck in months

HPA axis recovery may take 6-18 months after tumor shrinkage with dopamine agonist therapy 10.

Critical Safety Points

1. Never delay glucocorticoid replacement while awaiting further testing—adrenal crisis carries significant mortality risk
2. Measure dexamethasone level if false-positive suppression test suspected (drug interactions with CYP3A4 inhibitors) 11
3. Rule out macroprolactin if clinical picture doesn't match prolactin level 1
4. Check for "hook effect" if very large tumor with unexpectedly low prolactin—requires serial dilution 1
5. Fludrocortisone is NOT indicated in secondary adrenal insufficiency (mineralocorticoid axis intact) 5